Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

UMIT-2: A Randomized, Multi-country, Adaptive Phase IIb Platform Trial to Determine the Efficacy and Safety of Therapeutics for Crimean-Congo Haemorrhagic Fever

NCT06860334 is registered in ClinicalTrials.gov with Liverpool School of Tropical Medicine as lead sponsor.

NCT NCT06860334
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06860334 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
UMIT-2: A Randomized, Multi-country, Adaptive Phase IIb Platform Trial to Determine the Efficacy and Safety of Therapeutics for Crimean-Congo Haemorrhagic Fever
Lead sponsor
Liverpool School of Tropical Medicine
Phase
Phase 2
Overall status
Recruiting
Start date
June 4, 2026
Completion date
August 31, 2028
Enrollment
378 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

crimean-congo hemorrhagic fever